Business Context and Reporting Period
Jasper Therapeutics, Inc. filed a Form 8-K dated April 13, 2023, reporting amendments to executive and director compensation arrangements. The filing does not report quarterly or annual operating results.
Material Agreements and Compensation Changes
- William Lis, Board Chair: The Company extended Mr. Lis’s service as Chairperson of the Board through March 15, 2024. His annual cash compensation for services under the service agreement was set at $125,000 per year, effective April 1, 2023.
- Ronald Martell, CEO and President: The employment agreement was amended to provide that, if Mr. Martell is terminated without “Cause” or resigns for “Good Reason” within 24 months after a qualifying change in control, all of his outstanding Company equity awards will fully vest, subject to his execution of a release in favor of the Company.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating-financial metrics. It also does not quantify the potential value of Mr. Martell’s equity awards or the aggregate cost of Mr. Lis’s amended compensation.
Outlook, Risks, and Unusual Items
The amendments may increase compensation obligations and potential equity dilution or compensation expense following a change in control. The filing does not provide management outlook or discuss the likelihood, timing, or financial impact of a change in control.
Investor Verification Items
- Review the complete Lis Amendment and Martell Amendment filed as Exhibits 10.1 and 10.2.
- Verify the definition of “Change in Control,” “Cause,” and “Good Reason,” and the conditions governing accelerated vesting.
- Assess the number, type, and potential value of Mr. Martell’s outstanding equity awards.
- Review subsequent filings for changes to executive compensation, equity awards, or change-in-control arrangements.